Actively Recruiting
Evaluating Safety and Activity of Risvutatug Rezetecan with Ivonescimab for Advanced Solid Tumors
Led by GlaxoSmithKline · Updated on 2026-09-23
184
Participants Needed
4
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new combination treatment called Risvutatug rezetecan Ris-Rez with ivonescimab for adults who have advanced solid tumors, including certain lung cancers. This early-phase clinical study aims to find out the safe doses, possible side effects, how the body processes these drugs, and which doses might best improve cancer treatment. The study is sponsored by GlaxoSmithKline and involves both Phase 1 and Phase 2 steps. Participants will receive Risvutatug rezetecan and ivonescimab as biological treatments given in a sequential manner. The study includes a dose escalation phase Phase 1 to determine safety and appropriate dosing, followed by a dose expansion phase Phase 2 to further evaluate the treatments effects. Tumor tissue samples are required for participants in the dose expansion phase for biomarker analysis, including the detection of B7 homolog 3 protein expression. Throughout the study, participants will be closely monitored with regular assessments of adverse events, vital signs, body weight, laboratory tests, heart function, and performance status for up to approximately 143 weeks. Researchers will measure treatment safety, dosing effects, objective response rates, disease control, progression-free survival, and overall survival. Blood samples will be collected to study how the drugs behave in the body and to check for immune responses. Participants may remain in the study for long-term follow-up and safety monitoring lasting up to around 169 weeks.
CONDITIONS
Brief Title
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here